CLAIM CARD
The curated corpus is dominated by observational cohort designs and mechanistic reviews; no completed, long-term mortality or hard-clinical-endpoint randomized controlled trial (RCT) of immunosenescence-directed therapy appears in the included set. For example, Zhong 2025 describes only the design and protocol of a tai-chi RCT in prefrail older adults, not final efficacy data, leaving the synthesis without a replicated human trial that reports all-cause mortality, incident disability, or confirmed infection endpoints. Consequently, the headline conclusion that 'mechanistic plausibility coexists with mixed or sparse human-RCT evidence' reflects the true state of this curated evidence base rather than an absence of existing trials elsewhere. The absence of such outcome-driven RCTs means the synthesis cannot quantify effect sizes for clinically meaningful endpoints, and any claim linking immunosenescence modulation to improved survival remains unsupported within this corpus.
Evidence grade: exploratory
Contradiction status: none
Publication: 826c8f08-fdc3-46b0-9acd-2f25f81d0d03
Provenance: Derivation Web chain
Citation Support
source_1Shimizu 2025source_2Rastgoo 2025source_3Padhiar 2024source_4Park 2026source_5Seah 2026